Abstract |
Nifekalant (NF), a pure K(+) channel blocker developed in Japan, has been reported to be effective in the treatment of life-threatening ventricular arrhythmias. We studied its efficacy in 18 men and 4 women with out-of-hospital ventricular fibrillation (VF) admitted to our emergency department between August 2001 and March 2004. The number of DC shocks delivered for out-of-hospital VF, serum Na(+) and K(+), arterial blood pH, and base excess were compared in 8 patients treated with NF, 0.3 mg/kg i.v. followed by a continuous intravenous (group N) versus 14 patients treated with lidocaine, 2 mg/kg, i.v. (group C). The two groups were similar with respect to their baseline characteristics. Sinus rhythm returned in 5 of 8 patients in group N versus 2 of 14 patients in group C (P < 0.05). These seven patients were admitted to the intensive care unit, though all died within 1 month. The results of this study suggest that NF may be effective in defibrillation of out-of-hospital VF, though controlled studies are needed to confirm our observations.
|
Authors | Masaki Igarashi, Tadashi Fujino, Miwako Toyoda, Keishi Sugino, Kenichirou Sasao, Shuichi Sasamoto, Takayuki Otsuka, Kenzaburo Kobayashi, Yoshifumi Okano, Katsunori Yosiwara, Nobuya Koyama |
Journal | Pacing and clinical electrophysiology : PACE
(Pacing Clin Electrophysiol)
Vol. 28 Suppl 1
Pg. S155-7
(Jan 2005)
ISSN: 0147-8389 [Print] United States |
PMID | 15683486
(Publication Type: Journal Article)
|
Chemical References |
- Anti-Arrhythmia Agents
- Pyrimidinones
- nifekalant
|
Topics |
- Adult
- Aged
- Anti-Arrhythmia Agents
(administration & dosage)
- Electric Countershock
- Emergency Treatment
- Female
- Humans
- Injections, Intravenous
- Male
- Middle Aged
- Pyrimidinones
(administration & dosage)
- Ventricular Fibrillation
(drug therapy, therapy)
|